Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for pulmonary hypertension. The company's lead product is YUTREPIA, an inhaled dry powder formulation of treprostinil indicated for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia also commercializes Remodulin, an established treprostinil product delivered via continuous intravenous and subcutaneous infusion. The company is developing L606, an investigational liposomal inhaled sustained-release formulation of treprostinil for PAH and PH-ILD, through a license agreement with Pharmosa Biopharm Inc.
The company operates primarily in the United States market. Liquidia was founded in 2004 and maintains headquarters in Morrisville, North Carolina, with approximately 170 full-time employees. The company is incorporated in Delaware and listed on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.66 | $-1.66 | -37.2% | |
| 2023 | $-1.21 | $-1.21 | -80.6% | |
| 2022 | $-0.67 | $-0.67 | +4.3% | |
| 2021 | $-0.70 | $-0.70 | +72.8% | |
| 2020 | $-2.57 | — | — |